Huasun(SZ:000790)2018-10-25 16:00Financial Performance - Net profit attributable to shareholders was CNY 6,313,370.12, representing a significant increase of 109.94% year-on-year [8]. - Operating revenue for the period was CNY 167,055,046.47, reflecting a growth of 14.79% compared to the same period last year [8]. - Basic earnings per share were CNY 0.0113, up 109.94% year-on-year [8]. - The company reported a net profit excluding non-recurring gains and losses of CNY 6,174,373.42, a year-on-year increase of 135.56% [8]. - Gross profit margin increased by 16.82 percentage points compared to the same period last year, driven by a higher sales proportion of traditional Chinese medicine products [18]. Cash Flow - The net cash flow from operating activities reached CNY 27,126,981.39, an increase of 116.21% year-to-date [8]. - Net cash flow from operating activities increased by CNY 194.45 million, primarily due to higher cash receipts from sales and reduced tax payments [19]. - Net cash flow from investing activities decreased by CNY 70.05 million, mainly due to reduced cash received from the disposal of fixed assets [20]. - Net cash flow from financing activities decreased by CNY 223.10 million, primarily due to increased net cash outflow from working capital loans [20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,033,797,888.53, a decrease of 22.04% compared to the end of the previous year [8]. - Cash and cash equivalents decreased by CNY 173.74 million, a decline of 39.18%, primarily due to repayment of bank loans of CNY 130 million and cash dividends of CNY 34.48 million paid during the reporting period [17]. - Prepayments increased by CNY 6.18 million, a growth of 106.67%, mainly due to prepayments made by subsidiaries for project costs [17]. - Inventory increased by CNY 21.21 million, up 32.35%, as the company stocked up on raw materials in response to market conditions [17]. - Other non-current assets increased by CNY 20.03 million, up 78.55%, due to capital contributions made for a PPP project [17]. Shareholder Information - The total number of shareholders at the end of the reporting period was 55,576 [12]. - The largest shareholder, Sichuan Huashen Group Co., Ltd., held 18.08% of the shares, totaling 101,301,165 shares [13]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period [14]. - The company has no overdue commitments from controlling shareholders or related parties during the reporting period [23]. Research and Development - Research and development expenses rose by CNY 7.30 million, an increase of 75.29%, reflecting the company's intensified focus on R&D and clinical trials [19]. Return on Investment - The weighted average return on net assets was 0.74%, a decrease of 10.76% compared to the previous year [8].